Gastric inhibitory peptide (GIP) is a gut hormone that helps regulate insulin after meals. Learn how GIP works, how it differs from GLP-1, and why it matters.
Gastric inhibitory peptide (GIP) is a hormone released by the small intestine after you eat, and it signals the pancreas to release insulin as blood sugar rises. Scientists now call it glucose-dependent insulinotropic polypeptide, because its effect on insulin turned out to be more important than its original name suggested. Along with GLP-1, it is one of the two main incretin hormones in the human body.
What Is Gastric Inhibitory Peptide and Where Does It Come From?
GIP is a 42-amino-acid hormone produced by specialized K cells that line the upper small intestine, mainly the duodenum and jejunum. Those cells sense incoming nutrients, especially fat and carbohydrates, and release GIP into the bloodstream within minutes of a meal.
Researchers first described the hormone in the 1970s. Early studies showed it could reduce stomach acid secretion, which is where the name gastric inhibitory peptide came from. Later work revealed its larger role in glucose metabolism, so the name was updated to glucose-dependent insulinotropic polypeptide while the three-letter abbreviation, GIP, stayed the same.
GIP receptors are found on pancreatic beta cells, fat cells, bone cells, and in the brain. Because its effects depend on how much glucose is in the blood, GIP is described as glucose-dependent.
What Does GIP Do in the Body?
GIP's best-understood job is amplifying insulin release after a meal. When blood sugar climbs, GIP tells beta cells to secrete more insulin, but only when glucose is genuinely high, so the hormone rarely causes low blood sugar by itself.
GIP also has several other effects that researchers continue to study:
- Insulin secretion: boosts glucose-stimulated insulin release from pancreatic beta cells.
- Glucagon release: can stimulate glucagon from alpha cells, which is one reason blocking GIP is being explored for diabetes.
- Fat metabolism: promotes fat storage in adipose tissue and may influence insulin sensitivity.
- Bone health: appears to support bone formation and may help protect against bone loss.
- Appetite and digestion: contributes to satiety signaling in the brain and can modestly slow stomach emptying.
Anyone who has looked up what does glucagon-like peptide 1 do will notice that the answer overlaps with GIP in several places, because both hormones act on the same incretin system. They are still separate molecules, made by different cells and with different strengths.
GIP vs. GLP-1: Key Differences
GLP-1 comes from L cells in the lower small intestine and colon, while GIP comes from K cells higher up in the gut. Both boost insulin, but they behave differently when it comes to glucagon and digestion.
| Feature | GIP | GLP-1 |
|---|---|---|
| Producing cells | K cells in the upper small intestine | L cells in the lower small intestine and colon |
| Amino acids | 42 | 30 in the main active form |
| Insulin effect | Increases, glucose-dependent | Increases, glucose-dependent |
| Glucagon effect | Stimulates glucagon release | Suppresses glucagon release |
| Gastric emptying | Modest slowing | Marked slowing |
| Appetite | May reduce, weaker alone | Strongly reduces |
| Prescription drugs | Tirzepatide (dual GIP/GLP-1 agonist) | Semaglutide, liraglutide, dulaglutide |
Tirzepatide is the first FDA-approved drug that activates both the GIP and GLP-1 receptors, and it is sold under the brand names Mounjaro and Zepbound.
Why GIP Matters for Weight Loss Drugs
GIP is not approved as a stand-alone weight loss treatment. Early attempts to use GIP receptor agonists for obesity produced disappointing results, and some research teams tested GIP receptor blockers instead.
The picture changed with dual agonists. The combination of GIP and GLP-1 activity has produced substantial weight loss in clinical trials, and some researchers believe the GIP portion may reduce the nausea and vomiting that limits GLP-1-only drugs. The exact mechanism is still debated.
This work is one example of what is peptide therapy, a broad category that includes hormones, receptor agonists, and other lab-made peptides used as medications. Those drugs require a prescription and are not the same as over-the-counter peptide supplements.
How GIP Is Studied and Used in Medicine
Scientists measure GIP levels in blood to study how the gut communicates with the pancreas, but GIP testing is mostly a research tool rather than a routine clinical lab order. Studies of type 2 diabetes and obesity often use a glucose tolerance test to look at the incretin response.
Current GIP research focuses on type 2 diabetes, obesity, bone density, fatty liver disease, and the gut-brain axis. Blocking GIP is being tested as a way to improve blood sugar control, while activating it is the approach used in combination drugs.
GIP itself is not sold as a supplement, and GIP is not available as an over-the-counter product in the United States.
Molecule names in this space overlap a lot. If you have ever searched what is c-peptide, that refers to a fragment released when the pancreas makes insulin, and it measures insulin production rather than incretin activity. People also ask is nad a peptide, and the answer is no: NAD+ is a dinucleotide coenzyme involved in energy metabolism, not a peptide hormone.
Safety and Side Effects of GIP-Related Drugs
Medications that activate GIP and GLP-1 receptors share a similar side effect profile: nausea, vomiting, diarrhea, and constipation, especially when the dose increases quickly. Most of these effects ease over time, but some people cannot tolerate the drugs at all.
More serious concerns reported with incretin drugs include pancreatitis, gallbladder disease, and loss of lean muscle mass during rapid weight loss. Anyone considering these medications should discuss personal risk factors, kidney function, and any history of pancreatic or thyroid disease with a healthcare professional.
Lifestyle factors such as protein intake, resistance training, sleep, and overall diet quality still shape long-term health outcomes no matter which medication someone uses. GIP research is moving quickly, so guidance from a clinician is the most reliable source for individual decisions.
Frequently Asked Questions
What is gastric inhibitory peptide in simple terms?
GIP is a hormone made by cells in the upper small intestine that gets released after you eat. It travels to the pancreas and helps trigger insulin release when blood sugar is high, and it also affects fat tissue, bone, and appetite.
Is GIP the same as GLP-1?
No. GIP and GLP-1 are separate incretin hormones produced by different cells in the gut. Both boost insulin, but GLP-1 slows stomach emptying more and suppresses glucagon, while GIP tends to stimulate glucagon release. Drugs such as tirzepatide target both receptors at once.
Does GIP help with weight loss?
GIP alone has not worked well as a weight loss drug, and some researchers have tested blocking it instead. The strongest weight loss results come from medications that combine GIP and GLP-1 activity, such as tirzepatide.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.